-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Initiates Coverage On Immunic with Outperform Rating, Announces Price Target of $45

Benzinga·08/17/2026 13:08:18
Listen to the news
Wedbush analyst Martin Fan initiates coverage on Immunic (NASDAQ:IMUX) with a Outperform rating and announces Price Target of $45.